Revista da Associacao Medica Brasileira (1992) · 2026
Gastrin-releasing peptide, neuromedin B, and symptom severity in adult attention-deficit hyperactivity disorder.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tozoğlu Elif Özcan, Özkaya Alev Lazoğlu
Аннотация
OBJECTIVE: Attention-deficit hyperactivity disorder is a neurodevelopmental disorder associated with metabolic and neuropeptidergic processes. Gastrin-releasing peptide and neuromedin B, which are bombesin-like peptides, have been studied only to a limited extent in adult attention-deficit hyperactivity disorder, despite their role in energy homeostasis and central nervous system function. The aim of this study was to evaluate gastrin-releasing peptide and neuromedin B levels in untreated adult attention-deficit hyperactivity disorder patients and to examine their relationship with clinical symptom severity.
METHODS: This cross-sectional study included 55 untreated adult attention-deficit hyperactivity disorder patients and 32 healthy controls. Attention-deficit hyperactivity disorder diagnoses were confirmed using SCID-5/CV and DIVA 2.0, and symptom severity was assessed using the Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale. Gastrin-releasing peptide and neuromedin B levels in fasting serum were measured using the ELISA method. Group comparisons, Pearson correlations, hierarchical regression, and receiver operating characteristic analyses were performed.
RESULTS: Gastrin-releasing peptide (22.83±24.18 pg/mL) and neuromedin B (1.83±2.86 pg/mL) levels were significantly lower in the attention-deficit hyperactivity disorder group compared to the control group (p=0.004 and p=0.037, respectively). Gastrin-releasing peptide and neuromedin B levels were negatively correlated with Attention-Deficit Hyperactivity Disorder Self-Report Scale total and subscale scores (p<0.001 for all). In regression analyses, gastrin-releasing peptide was an independent predictor of Attention-Deficit Hyperactivity Disorder Self-Report Scale total score (β=-0.642, p=0.024). In receiver operating characteristic analyses, gastrin-releasing peptide (AUC=0.746) and neuromedin B (AUC=0.719) showed significant performance in distinguishing attention-deficit hyperactivity disorder.
CONCLUSION: The findings suggest that gastrin-releasing peptide, in particular, may be associated with clinical symptom severity in adult attention-deficit hyperactivity disorder and is a potential biomarker candidate.
METHODS: This cross-sectional study included 55 untreated adult attention-deficit hyperactivity disorder patients and 32 healthy controls. Attention-deficit hyperactivity disorder diagnoses were confirmed using SCID-5/CV and DIVA 2.0, and symptom severity was assessed using the Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale. Gastrin-releasing peptide and neuromedin B levels in fasting serum were measured using the ELISA method. Group comparisons, Pearson correlations, hierarchical regression, and receiver operating characteristic analyses were performed.
RESULTS: Gastrin-releasing peptide (22.83±24.18 pg/mL) and neuromedin B (1.83±2.86 pg/mL) levels were significantly lower in the attention-deficit hyperactivity disorder group compared to the control group (p=0.004 and p=0.037, respectively). Gastrin-releasing peptide and neuromedin B levels were negatively correlated with Attention-Deficit Hyperactivity Disorder Self-Report Scale total and subscale scores (p<0.001 for all). In regression analyses, gastrin-releasing peptide was an independent predictor of Attention-Deficit Hyperactivity Disorder Self-Report Scale total score (β=-0.642, p=0.024). In receiver operating characteristic analyses, gastrin-releasing peptide (AUC=0.746) and neuromedin B (AUC=0.719) showed significant performance in distinguishing attention-deficit hyperactivity disorder.
CONCLUSION: The findings suggest that gastrin-releasing peptide, in particular, may be associated with clinical symptom severity in adult attention-deficit hyperactivity disorder and is a potential biomarker candidate.